About

Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 25 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. He currently serves on the board of directors of IMV Inc., a clinical-stage biopharmaceutical company developing a new class of cancer immunotherapies and vaccines to treat infectious diseases such as COVID-19. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems’ (now Eli Lilly) Worldwide Commercial Organization. During his nine-year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham’s Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.

Lisa Bruneau brings to AVEO more than 20 years of financial and public company experience in the life sciences industry. She joined AVEO in 2016 as the Vice President of Financial Accounting and Reporting and Treasurer. Ms. Bruneau joined AVEO from Synta Pharmaceuticals, where she served as Senior Director of Finance and Director of Finance since 2004, including the company’s initial public offering. Prior to Synta, Ms. Bruneau worked at Diomed and Acambis (formerly OraVax) where she held various positions of increasing responsibility in finance and accounting, including OraVax’s initial public offering. Ms. Bruneau holds a B.S. in Business, Accounting and Finance from Bridgewater State College and an M.B.A. in International Business from Suffolk University in Boston.

Matthew Coulter comes to AVEO with more than 25 years of experience integrating the finance and IT roles in companies ranging from Fortune 500 enterprises to pharmaceutical startups. Most recently, he led internal and external IT operations for startup Zealand Pharma as it brought its insulin pump to market, and he helped build field sales and manufacturing infrastructures to support growth to tens of millions of dollars in annual revenue. Matt has written and implemented custom software to streamline processes in ERP, supply chain, HR, and manufacturing functions, and he has digitized accounting functions to increase efficiency. Matt holds a Bachelor of Science in Finance, Economics, and Entrepreneurial Studies form Babson College in Wellesley, MA.

David Crist brings more than twenty years of oncology sales experience in both launch-stage and late-stage companies, building commercial organizations and developing high performing sales force teams. During his career, Mr. Crist held oncology-focused sales roles at several leading pharmaceutical companies including MGI (Molecular Genetics, Inc), Eisai, Sanofi Genzyme, GlaxoSmithKline and ARIAD Pharmaceuticals, where he led their sales organization in the successful relaunch of  ICLUSIG^® (ponatinib), which contributed to the acquisition of ARIAD by Takeda Oncology in 2017. Following the acquisition, he continued at Takeda to successfully launch ALUNBRIG^® (brigatinib), which exceeded launch year and subsequent year forecasts nationally. Directly prior to joining AVEO, Mr. Crist served as general manager, hematology oncology U.S. franchise at argenx, a global immunology company, where he led commercial development for two of the company’s hematology and oncology compounds. Mr. Crist holds a B.S. from Florida State University.

Sinai Davis, M.D. serves as Vice President, Global Head of Pharmacovigilance at AVEO Oncology. He brings more than 20 years of experience in drug and medical device safety. Dr. Davis started his career at the US Food & Drug Administration as a Consumer Safety Officer/Investigator at the NJ District Office in Parsippany, NJ. After 6 years at the agency, Dr. Davis took his experience and knowledge to industry and has been the Head of Safety at five pharma/biotech companies. He has experience in 10 therapeutic and three medical device areas and has been the drug safety physician on three successful NDAs. Dr. Davis has discovered two signals that required labeling changes including a Black Box Warning. He has built safety teams and developed systems, processes, and procedures to run successful pharmacovigilance departments. Dr. Davis received his B.S. Degree in Microbiology from The University of Alabama and his Medical Degree from C.E.U.X. School of Medicine.

Catherine DeRose joined AVEO in September 2020 as Vice President of Human Resources and brings to the company extensive Human Resources, Organizational Leadership and Operational experience across various industries, including medical devices, pharmaceutical manufacturing/packaging, and consumer products. She has led domestic and global teams through transition and growth in positions of progressive responsibility including Vice President of Supply Chain/Human Resources at AmerTac, Global Director of Human Resources at Flash Global and Senior Director of Human Resources with Zealand Pharma (formerly Valeritas).

Catherine holds a B.A. from Arcadia University, an M.S.A. from Central Michigan University and is a SHRM-SCP Certified Human Resources Professional and Six Sigma Green Belt.

Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.

Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations. He has over 20 years of commercial pharmaceutical and biotechnology experience, including 15 years developing and commercializing oncology products. At AVEO, in addition to developing the Company’s commercial strategy and infrastructure, Mr. Ferraresso has played a key role in business development activities, including the Company’s immuno-oncology clinical collaborations and the over $400 million agreement amendment with Kyowa Kirin for non-oncology rights to tivozanib in AVEO’s territories. Prior to joining AVEO, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics, and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing, and field deployment models and has launched Oprapred^™, Plenaxis^™, Zyflo^™ and Feraheme^™. Mr. Ferraresso holds a BA degree in Economics from Assumption College.

Julie Harrison, ASQ, CQA, brings over 20 years of regulated industry experience to her role as AVEO’s Vice President, GXP Quality Assurance, including pharmaceuticals and medical device operations, project management, quality systems, validation, and drug product commercialization. Prior to joining AVEO, Ms. Harrison served as Director, Quality Assurance at Stealth Biotherapeutics managing the QA responsibilities for commercialization of both US- and EU-based drug products.

Julie has also been responsible for QA-related commercialization activities with previous companies including Acambis, supporting the licensure of ACAM2000™. In addition to these positions within operating companies, Julie has also served as a lead consultant to various pharmaceutical and medical device companies including Pfizer, Getinge and Genzyme. Julie holds a B.S. in Health Sciences from Quinnipiac University, and an A.A. in Biotechnology from North Shore Community College.

Danielle Holland serves as Vice President of Legal and Corporate Secretary of AVEO. Prior to joining AVEO, Ms. Holland served as an Associate at Skadden, Arps, Slate, Meagher & Flom LLP where she advised public and private clients in a variety of industries in corporate and securities law matters, mergers and acquisitions, governance, corporate finance and other matters. Prior to her legal career, Ms. Holland taught elementary education in New York City through Teach For America. Ms. Holland received a B.A. in International Studies from Boston College and a J.D. from Boston University School of Law.

Dr. Vijay Kasturi, Vice President, Medical Affairs, brings more than 25 years of experience establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology. Prior to joining AVEO, Dr. Kasturi was Senior Vice President of Scientific Affairs at FerGene, where he also led both Medical Affairs and Clinical Development. He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer.

Earlier in his career, Dr. Kasturi served as an Assistant Professor of Medicine, Division of Hematology-Oncology  at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock Medical Center.

Mr. Ledell serves as Chief Operating Officer of AVEO. He joins AVEO from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as Chief Operating Officer and led key business operations during the recent U.S. Food and Drug Administration approval of RETHYMI^®. Prior to Enzyvant, Mr. Ledell served as the Chief operating officer at Compass Therapeutics and Horizon Discovery Group. He was responsible for leading operations at both organizations through several changes in scale. Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc. Mr. Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.

Erick Lucera brings to AVEO over twenty years of financial, operational, and investment experience in the biotechnology and medical device industries. He most recently served as chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as the chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly $250 million. Previously, Mr. Lucera was vice president, corporate development at Sunshine Heart (now CHF Solution), a medical device manufacturer.

Prior to Sunshine Heart, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co. (now PwC). Mr. Lucera holds a CPH from Harvard University, an MS from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera currently holds a CFA designation. Mr. Lucera previously held CMA and CPA designations, which are expired.

Barbara Natke serves as Vice President of Business Development and bringing more than 20 years of Biotech/Pharma experience to AVEO.  Prior to joining AVEO, Dr. Natke served as the Vice President of Business Development at Samyang Biopharm, USA where she was responsible for creating a pipeline of transformative oncology therapies for the newly established US entity of the Samyang Holdings Corporation.  Prior to Samyang, Dr. Natke served in a variety of roles of increasing responsibility in the Shire/Takeda organization including Scientific Director and Due Diligence Lead.  Before making the transition to the business side of the Pharma industry, Barbara spent 8 years running laboratory groups at Genzyme/Sanofi following her post-doctoral studies at the Massachusetts Institute of Technology.  Dr. Natke holds a PhD in Biochemistry from Boston University School of Medicine and an MBA from Babson College.  

Jason Noto brings over 20 years of broad commercial leadership experience to his role as Vice President of Market Access at AVEO Oncology. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, patient support services (HUB), payer contract development and assessment, financial impact analysis, and related Access functions. Earlier, Jason served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading Payer marketing efforts across all business units totaling >$600M in revenue in 2019.

Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various launch, in-line, and multi-channel marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol-Myers Squibb Company. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, & ultra-orphan disease states. Mr. Noto received a B.S. in Business Administration from Le Moyne College and an M.B.A. in finance from the Carroll School of Management at Boston College.

Manoj Patel has more than 20 years of experience in the pharmaceutical industry, over 15 of which are directly in the development of oncologic treatments and joins AVEO as Vice President of Program Management. Prior to joining AVEO’s management team, Dr. Patel led the development of several biologics programs as a Project Leader within Teva’s specialty pharma group. Prior to Teva, he held several senior level positions within Project and Program Management as well as Customer Solutions at PRA Health Sciences (now part of ICON) and IQVIA. During his tenure at these CROs, Dr. Patel oversaw the development of oncology treatments for several major pharmaceutical and biotech clients. Prior to IQVIA, he worked at GlaxoSmithKline for more than 10 years across multiple functions that included Clinical Development, Medical Affairs and Project Management. Dr. Patel was also Sr. Director of Program and Alliance Management at ImClone Systems and was involved in the process leading to the ultimate sale of the company to Eli Lilly. Dr. Patel received BS degrees in Chemistry and Pharmacy from the University of North Carolina at Chapel Hill and a Doctorate of Pharmacy from Campbell University.